GENERIC NAME: Urokinase
BRAND NAME: Kinlytic (This drug is discontinued in the US)
DRUG CLASS AND MECHANISM: Urokinase is a thrombolytic medication made from human neonatal kidney cells. Urokinase is an enzyme (protein) that disrupts the clotting cycle and breaks down blood clots lodged in the lungs in people with pulmonary embolism. The FDA approved urokinase under the brand name Kinlytic in 2007.
GENERIC AVAILABLE: Not in U.S.
PREPARATIONS: Urokinase available as sterile, lyophilized powder for solution for intravenous administration. Each vial contains 250,000 international units of urokinase activity.
STORAGE: Store urokinase vials in the fridge between 2 C to 8 C (36 F to 46 F).
PRESCRIBED FOR: Urokinase is prescribed for breakdown of pulmonary emboli, which are clots lodged in the lungs.
DOSING: Administer a loading dose of 4400 international units per kg intravenously over 10 minutes, followed by a continuous administration of 4400 international units per kg per hour intravenously for 12 hours. Repeat as necessary.
Safe and effective use of urokinase is not established for children.
DRUG INTERACTIONS: Urokinase should be used with caution with other medications that alter platelet function and increase risk of bleeding. Medications like aspirin, ibuprofen (Motrin), naproxen (Aleve, Naprosyn), warfarin (Coumadin), enoxaparin (Lovenox), clopidogrel (Plavix), and cilostazol (Pletal) should be used with caution with urokinase.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.